Pharma Companies Need to Keep Improving AIDS Response, Says ICCR and Nigerian Doctor
Author: William Baue, SocialFunds, Published on: 1 December 2006
In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) produced the most thorough study of pharmaceutical company action on HIV/AIDS, documenting how the industry falls significantly short of best practice...The Business and Human Rights Resource Centre posted the report along with company responses to it on its website. [The following companies sent responses: Abbott Laboratories; AstraZeneca; GlaxoSmithKline; Boehringer-Ingelheim; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Tibotec (part of Johnson & Johnson), Wyeth. The following did not respond: Eli Lilly; Gilead Sciences; Hoffman-La Roche; sanofi-aventis; Schering-Plough.]...[The Resource Centre] recently added a paper by Dr. Chukwumuanya Igboekwu...of Physicians for Social Justice (PSJ) in Nigeria...in which he identifies patent protection...as a persisting problem in pharma companies' response to AIDS...Dr. Igboekwu cites the case of Novartis filing a lawsuit in India to protect patents covering certain of its cancer drugs...The...Resource Centre posted a response...from Novartis...
Related companies: Abbott Laboratories AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb Eli Lilly Gilead Sciences GlaxoSmithKline Hoffmann-La Roche (part of Roche) Johnson & Johnson Novartis Pfizer Sanofi Schering-Plough Tibotec (part of Johnson & Johnson)